aflibercept (Eylea, Regeneron Pharmaceuticals)

Observations may provide evidence of systemic effect of anti-VEGF therapyIntravitreal aflibercept may be associated with systemic effects based on an observable reaction in the fellow eyes of patients with diabetic macular edema.
FDA grants priority review to aflibercept for diabetic retinopathy in patients with DMEThe FDA has accepted for priority review Regeneron Pharmaceuticals’ supplemental biologics license application for aflibercept (Eylea) injection, a treatment of diabetic retinopathy in patients with diabetic macular edema (DME).
Health Canada approves Eyelea for DME treatmentHealth Canada recently approved Eylea (aflibercept, Regeneron) for the treatment of diabetic macular edema (DME).
Primary care optometry: addressing the posterior segmentDuring the American Academy of Optometry's Academy 2014, experts elucidated with promising directions for retinal and other posterior eye problems.
AMD patients respond to aflibercept treatmentA study recently published in the British Journal of Ophthalmology found that patients with exudative age-related macular degeneration (AMD) who were incomplete responders to multiple ranibizumab injections (Lucentis, Genentech) saw improvements with aflibercept (Eylea, Regeneron) treatment.
ADA: Intravitreal aflibercept injection shows consistency of effect across levels of HbA1c control in diabetic macular edemaPatients with diabetic macular edema (DME) treated with aflibercept Injection significantly improved vision and reduced the severity of diabetic retinopathy versus laser photocoagulation, according to data recently presented the American Diabetes Association (ADA) Scientific Sessions in San Francisco.
Aflibercept acuity gains rival laser for BRVOMonthly injections yielded superior vision increases, marked retinal thickness decreases
  • 1
  • 2